56, 2, 3, 19, 20, 21, 60 or 61. The polypeptide may have a maximum length of 9, 10, 15, 20, 25, 30, 35, 40, 45 or 50 amino acids and/or in which the C terminal amino acid is replaced with the corresponding amide. The polypeptide may be isolated.

The present disclosure also provides a polypeptide which is an immunogenic fragment of murine Arginase2 (SEQ ID NO: 52) that comprises or consists of a sequence of at least 9 consecutive amino acids of SEQ ID NO: 52 which (i) include at least the amino acids at positions 21, 22 and 23 of SEQ ID NO: 52, or (ii) are selected from positions 180 – 229 of SEQ ID NO: 52. The polypeptide may comprise or consist of up to 15, 20, 25, 30, 35, 40, 45 or 50 consecutive amino acids of SEQ ID NO: 52 as defined in (i) or (ii). The polypeptide may have a maximum length of 9, 10, 15, 20, 25, 30, 35, 40, 45 or 50 amino acids and/or in which the C terminal amino acid is replaced with the corresponding amide. The polypeptide may be isolated.

The present disclosure also provides a composition comprising a polypeptide of the disclosure, at least one pharmaceutically acceptable diluent, carrier or preservative, and optionally an adjuvant.

The present disclosure also provides a method of treating or preventing a disease or condition in a subject, the method comprising administering to the subject a polypeptide or a composition of the disclosure.

Thus, in one aspect, the present disclosure refers to a polypeptide which is an immunogenic fragment of human Arginase2 (SEQ ID NO: 51) that comprises or consists of a sequence of at least 9 consecutive amino acids of SEQ ID NO: 51 which ~~(i)~~ include at least the amino acids at positions 21, 22 and 23 of SEQ ID NO: 51~~, or (ii) are selected from positions 180 – 229 of SEQ ID NO: 51~~.

In another aspect, the present disclosure refers to a composition comprising the polypeptide as disclosed herein and an adjuvant.

In another aspect, the present disclosure refers to a composition as disclosed herein, comprising at least one pharmaceutically acceptable diluent, carrier or preservative.

In another aspect, the present disclosure refers to a composition as disclosed herein wherein the adjuvant is selected from the group consisting of bacterial DNA based adjuvants, oil/surfactant based adjuvants, viral dsRNA based adjuvants, ~~imidazochinilines~~imidazoquinolines, and a Montanide ISA adjuvant.

In another aspect, the present disclosure refers to the use of the polypeptide as disclosed herein or the composition as disclosed herein in the manufacture of a medicament for treating a ~~disease or condition which is characterized at least in part by inappropriate or excessive immune suppressive function of Arginase2, and/or wherein said disease or condition is~~ cancer.

In another aspect, the present disclosure refers to a method of stimulating arginase2-specific T cells, the method comprising contacting the cells with the polypeptide as disclosed herein or the composition as disclosed herein, ~~optionally wherein the cells are present in a sample taken from a healthy subject or from a cancer patient, optionally a tumour sample~~wherein the method is performed *ex vivo*.

In yet another aspect, the present disclosure refers to a nucleic acid encoding a polypeptide as disclosed herein.

Brief description of the Figures

CLAIMS

1. A polypeptide which is an immunogenic fragment of human Arginase2 (SEQ ID NO: 51) that comprises or consists of a sequence of at least 9 consecutive amino acids of SEQ ID NO: 51 which ~~(i)~~ include at least the amino acids at positions 21, 22 and 23 of SEQ ID NO: 51~~, or (ii) are selected from positions 180 – 229 of SEQ ID NO: 51~~.

2. The polypeptide of claim 1 which comprises or consists of up to 15, 20, 25, 30, 35, 40, 45 or 50 consecutive amino acids of SEQ ID NO: 51 ~~as defined in (i) or (ii)~~.

3. The polypeptide of claim 1 or 2 which comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 59, 58, 57, 54, 55, 56, 2~~,~~ or 3~~, 19, 20, 21, 60 or 61~~.

4. The polypeptide of any one of the preceding claims, which has a maximum length of 9, 10, 15, 20, 25, 30, 35, 40, 45 or 50 amino acids and/or in which the C terminal amino acid is replaced with the corresponding amide.

5. A composition comprising the polypeptide of any one of the preceding claims and an adjuvant.

6. A composition according to claim 5, comprising at least one pharmaceutically acceptable diluent, carrier or preservative.

7. A composition according to claim 5 or 6 wherein the adjuvant is selected from the group consisting of bacterial DNA based adjuvants, oil/surfactant based adjuvants, viral dsRNA based adjuvants, ~~imidazochinilines~~imidazoquinolines, and a Montanide ISA adjuvant.

8. The polypeptide of any one of claims 1 to 4 or the composition of any one of claims 5 to 7 for use in therapy.

9. Use of the polypeptide of any one of claims 1 to 4 or the composition of any one of claims 5 to 7 in the manufacture of a medicament for treating a ~~disease or condition which is characterized at least in part by inappropriate or excessive immune suppressive function of Arginase2, and/or wherein said disease or condition is~~ cancer.

10. The use of claim 9, ~~wherein the disease or condition is cancer and optionally~~ wherein the use further comprises the simultaneous or sequential administration of an additional cancer therapy.

11. The use of claim 10 wherein the additional cancer therapy is an immune system checkpoint inhibitor~~, preferably~~.

12. The use of claim 11, wherein the immune system checkpoint inhibitor is an antibody.

~~12~~13. The use of claim ~~11~~ 12 wherein the antibody is an anti-PD1 antibody.

~~13~~14. The use of any one of claims 9 to ~~12~~ 13 wherein said cancer is cancer of the kidney, prostate, breast, brain, head and neck, or small intestine, or is a colorectal or gastric cancer, or is a melanoma, or is a leukemia~~, preferably~~.

15. The use of claim 14, wherein the leukemia is acute myeloid leukemia (AML)~~, optionally~~.

16. The use of claim 14, wherein the cancer is resistant to treatment with an immune system checkpoint inhibitor.

~~14~~17. A method of stimulating arginase2-specific T cells, the method comprising contacting the cells with the polypeptide of any one of claims 1 to 4 or the composition of claim 5 to 7, ~~optionally~~wherein the method is performed *ex vivo*.

18. The method of claim 17, wherein the cells are present in a sample taken from a healthy subject or from a cancer patient~~, optionally~~.

19. The method of claim 17, wherein the cells are present in a tumour sample.

~~15~~20. A nucleic acid encoding a polypeptide according to any one of claims 1 to 4.